Dr. Schneider is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Summary
- Dr. Bryan Schneider is an oncologist in Ann Arbor, MI and is affiliated with Michigan Medicine. He received his medical degree from Indiana University School of Medicine and has been in practice 19 years. He specializes in hematologic oncology and is experienced in medical oncology, thoracic oncology, general medical oncology, and lung neoplasms.
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 2002 - 2005
- Indiana University School of MedicineResidency, Internal Medicine, 1998 - 2002
- Indiana University School of MedicineClass of 1998
Certifications & Licensure
- MI State Medical License 2005 - 2027
- NY State Medical License 2008 - 2016
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors Start of enrollment: 2009 Jul 01
- BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review.Alessandro Villa, Bryan J Schneider, Christina Lacchetti, Thomas K Oliver, Douglas E Peterson
British Journal of Cancer. 2025-01-01 - Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer.Donna M Edwards, Caitlin A Schonewolf, John D Rice, Matthew Schipper, Randall K Ten Haken
International Journal of Radiation Oncology, Biology, Physics. 2024-12-01 - NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.John A Thompson, Bryan J Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi
Journal of the National Comprehensive Cancer Network. 2024-11-01
Lectures
- Implications of incidental germline findings identified in the context of clinical whole exome sequencing (WES) for guiding cancer therapy.2019 ASCO Annual Meeting - 6/1/2019
- Review and Interpretation of the 2012 San Antonio Breast Cancer SymposiumIndiana University School of Medicine, Indianapolis, Indiana - 1/19/2013
Press Mentions
- Manatt Expands National Health Care Capabilities with Arrival of Prominent Litigator in ChicagoOctober 7th, 2021
- ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLCNovember 16th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: